^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

DAN-222

i
Other names: DAN-222, camptothecin conjugated polymeric nanoparticle
Company:
Dantari
Drug class:
Topoisomerase I inhibitor
Related drugs:
Phase 2
QuantumLeap Healthcare Collaborative
Recruiting
Last update posted :
10/22/2024
Initiation :
03/01/2010
Primary completion :
12/01/2030
Completion :
12/01/2031
HER-2 • ER
|
ER positive • ER negative
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
Phase 1
Dantari, Inc.
Completed
Last update posted :
12/13/2023
Initiation :
02/02/2022
Primary completion :
09/13/2023
Completion :
10/11/2023
HER-2
|
HER-2 positive • HER-2 negative
|
Zejula (niraparib) • DAN-222